Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of GLPG1690 in Healthy Males
NCT02179502Phase 1Completed
- Sponsor
- Galapagos NV
- Start
- Jun 2014
- Primary completion
- Nov 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ziritaxestat in idiopathic pulmonary fibrosis (IPF) (4 arms), sponsored by Galapagos NV. Primary endpoints: Number of subjects with adverse events, Number of subjects with abnormal laboratory parameters and 2 more. Started Jun 2014; status: completed.
02
Drugs
ziritaxestat
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT02179502.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02179502.